SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: GlobeNewswire
ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. “We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clinical development program for the BIM-IOL system,” said Patrick Mooney, Chief Executive Officer of SpyGlass Pharma. “Jean’s deep experience in driving successful late-stage development investment while advancing clinical pipelines will be instrumental at this point in the company’s journey.” Dr. Vi
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)GlobeNewswire
- Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal CarcinomaGlobeNewswire
- Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic AntibodyGlobeNewswire
CHRS
Earnings
- 11/6/25 - Beat
CHRS
Sec Filings
- 12/9/25 - Form EFFECT
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- CHRS's page on the SEC website